The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus

Current Opinion in Immunology

Volumn 12, Issue 4, 2000, Pages 474-478

  Howie, Duncan ^a   Sayos, Juan ^a   Terhorst, Cox ^a   Morra, Massimo ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR;

CRYSTAL STRUCTURE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOGENETICS; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR CLONING; NONHUMAN; REVIEW; T LYMPHOCYTE; X CHROMOSOME LINKAGE;

ANTIGENS, CD; CARRIER PROTEINS; CLONING, MOLECULAR; GENE DELETION; GLYCOPROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOPROLIFERATIVE DISORDERS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES;

EID: 0034083774     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00123-0     Document Type: Review

References (36)

1. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell. 77:1994;791-793.
2. Purtilo D.T., Cassel C.K., Yang J.P., Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet. 1:1975;935-940.
3. Hamilton J.K., Paquin L.A., Sullivan J.L., Maurer H.S., Cruzi F.G., Provisor A.J., Steuber C.P., Hawkins E., Yawn D., Cornet J.A.et al. X-linked lymphoproliferative syndrome registry report. J Pediatr. 96:1980;669-673.
4. Strahm B., Rittwieiler K., Duffner U., Brandau O., Orlowska-Volk M., Karajannis M.A. Stadt Uz, Tiemann M, Reiter A, Brandis M et al.: Recurrent B-cell non-Hodgkin's lymphoma in two brothers with X-linked lymphoproliferative disease without evidence for Epstein-Barr virus infection. Br J Haematol. 108:2000;377-382.
5. Brandau O., Schuster V., Weiss M., Hellebrand H., Fink F.M., Kreczy A., Friedrich W., Strahm B., Niemeyer C., Belohradsky B.H.et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet. 8:1999;2407-2413.
6. Grierson H.L., Skare J., Hawk J., Pauza M., Purtilo D.T. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease. Am J Med Genet. 40:1991;294-297.
7. Fleisher G., Starr S., Koven N., Kamiya H., Douglas S.D., Henle W. A non-X-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr. 100:1982;727-730.
8. Henter J., Elinder G. Familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 80:1991;269-277.
9. Stepp S.E., Dufourcq-Lagelouse R., Le Deist F., Bhawan S., Certain S., Mathew P.A., Henter J.I., Bennett M., Fischer A., de Saint Basile G., Kumar V. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 286:1999;1957-1959.
10. Gross T.G., Filipovich A.H., Conley M.E., Pracher E., Schmiegelow K., Verdirame J.D., Vowels M., Williams L.L., Seemayer T.A. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant. 17:1996;741-744.
11. Arkwright P.D., Makin G., Will A.M., Ayres M., Gokhale D.A., Fergusson W.D., Taylor G.M. X linked lymphoproliferative disease in a United Kingdom family. Arch Dis Child. 79:1998;52-55.
12. Coffey A.J., Brooksbank R.A., Brandau O., Oohashi T., Howell G.R., Bye J.M., Cahn A.P., Durham J., Heath P., Wray P.et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 20:1998;129-135.
13. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., van Schaik S., Notarangelo L., Geha R., Roncarolo M.G.et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:1998;462-469.
14. Skare J.C., Grierson H.L., Sullivan J.L., Nussbaum R.L., Purtilo D.T., Sylla B.S., Lenoir G.M., Reilly D.S., White B.N., Milunsky A. Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. Hum Genet. 82:1989;354-358.
15. Wyandt H.E., Grierson H.L., Sanger W.G., Skare J.C., Milunsky A., Purtilo D.T. Chromosome deletion of Xq25 in an individual with X-linked lymphoproliferative disease. Am J Med Genet. 33:1989;426-430.
16. Sanger W.G., Grierson H.L., Skare J., Wyandt H., Pirruccello S., Fordyce R., Purtilo D.T. Partial Xq25 deletion in a family with the X-linked lymphoproliferative disease (XLP). Cancer Genet Cytogenet. 47:1990;163-169.
17. Skare J., Wu B.L., Madan S., Pulijaal V., Purtilo D., Haber D., Nelson D., Sylla B., Grierson H., Nitowsky H.et al. Characterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics. 16:1993;254-255.
18. Wu C., Sayos J., Wang N., Howie D., Coyle A., Terhorst C. Genomic organization and characterization of mouse SAP: the gene that is altered in X-linked lymphoproliferative disease. Immunogenetics. 2000;. in press.
19. Nichols K.E., Harkin D.P., Levitz S., Krainer M., Kolquist K.A., Genovese C., Bernard A., Ferguson M., Zuo L., Snyder E.et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA. 95:1998;13765-13770.
20. Poy F., Yaffe M.B., Sayos J., Saxena K., Morra M., Sumegi J., Cantley L.C., Terhorst C., Eck M.J. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell. 4:1999;555-561. This paper shows for the first time the crystal structure of SAP in complex with a peptide of SLAM, giving structural explanations of SAP SH2-domain binding to non-tyrosine-phosphorylated SLAM. Poy et al. also identify the optimal binding motif of SAP.
21. Li S.C., Gish G., Yang D., Coffey A.J., Forman-Kay J.D., Ernberg I., Kay L.E., Pawson T. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A. Curr Biol. 9:1999;1355-1362. Li et al. indicate a model of SAP binding to the proximal tyrosine residue of SLAM in a 'three pronged' fashion, through extended amino-terminal and carboxy-terminal stabilizing interactions.
22. Tangye S.G., Lazetic S., Woollatt E., Sutherland G.R., Lanier L.L., Phillips J.H. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol. 162:1999;6981-6985. Tangye et al. report the binding of SAP to the NK molecule 2B4.
23. Cocks B.G., Chang C.C., Carballido J.M., Yssel H., de Vries J.E., Aversa G. A novel receptor involved in T-cell activation. Nature. 376:1995;260-263.
24. Sidorenko S.P., Clark E.A. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol. 151:1993;4614-4624.
25. Aversa G., Chang C.C., Carballido J.M., Cocks B.G., de Vries J.E. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J Immunol. 158:1997;4036-4044.
26. Carballido J.M., Aversa G., Kaltoft K., Cocks B.G., Punnonen J., Yssel H., Thestrup-Pedersen K., de Vries J.E. Reversal of human allergic T helper 2 responses by engagement of signaling lymphocytic activation molecule. J Immunol. 159:1997;4316-4321.
27. Punnonen J., Cocks B.G., Carballido J.M., Bennett B., Peterson D., Aversa G., de Vries J.E. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med. 185:1997;993-1004.
28. Isomaki P., Aversa G., Cocks B.G., Luukkainen R., Saario R., Toivanen P., de Vries J.E., Punnonen J. Increased expression of signaling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol. 159:1997;2986-2993.
29. Ferrante P., Fusi M.L., Saresella M., Caputo D., Biasin M., Trabattoni D., Salvaggio A., Clerici E., de Vries J.E., Aversa G.et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol. 160:1998;1514-1521.
30. Mikhalap S.V., Shlapatska L.M., Berdova A.G., Law C.L., Clark E.A., Sidorenko S.P. CDw150 associates with src-homology 2- containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol. 162:1999;5719-5727.
31. Isomaki P., Aversa G., Chang C.C.J., Luukkainen R., Nikkari S., Toivanen P., de Vries J.E., Punnonen J. Expression of soluble human signaling lymphocytic activation molecule in vivo. J Allergy Clin Immunol. 103:1999;114-118.
32. Mathew P.A., Garni-Wagner B.A., Land K., Takashima A., Stoneman E., Bennett M., Kumar V. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol. 151:1993;5328-5337.
33. Latchman Y., McKay P.F., Reiser H. Identification of the 2B4 molecule as a counter-receptor for CD48. J Immunol. 161:1998;5809-5812.
34. Brown M.H., Boles K., Anton van der Merwe P., Kumar V., Mathew P.A., Barclay A.N. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 188:1998;2083-2090.
35. Fisher R.C., Thorley-Lawson D.A. Characterization of the Epstein-Barr virus-inducible gene encoding the human leukocyte adhesion and activation antigen BLAST-1 (CD48). Mol Cell Biol. 11:1991;1614-1623.
36. Garni-Wagner B.A., Purohit A., Mathew P.A., Bennett M., Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol. 151:1993;60-70.